Related Experiment Video
Updated: Aug 10, 2026
Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
Published on: March 2, 2011
Bioassay vs. immunoassay for quantification of interleukin-6 in biological fluids
N G Papadopoulos1, G V Dedoussis, C N Baxevanis
1Immunology Department, Hellenic Anticancer Institute, Athens, Greece.
Insights
Comparing interleukin-6 (IL-6) quantification methods, this study found enzyme immunoassays suitable for routine use, while bioassays offer higher sensitivity for specific applications. Both methods showed good correlation across various patient groups.
Area of Science:
- Biotechnology
- Immunology
- Clinical Chemistry
Background:
- Interleukin-6 (IL-6) has potential prognostic and therapeutic applications, necessitating reliable quantification methods.
- Accurate measurement of IL-6 in biological fluids is crucial for clinical research and patient management.
Purpose of the Study:
- To compare the performance of the 7TD1 hybridoma bioassay and an enzyme immunoassay for quantifying interleukin-6.
- To evaluate these methods across diverse biological samples and patient populations.
Main Methods:
- Comparative analysis of 7TD1 hybridoma bioassay and enzyme immunoassay.
- Quantification of IL-6 in serum, plasma, malignant pleural effusions, and culture supernatants.
- Inclusion of normal subjects and patients with cancer, sepsis, and systemic lupus erythematosus.
Main Results:
- A good correlation was observed between the bioassay and immunoassay results across all sample types and patient groups.
- Statistically significant differences in mean IL-6 values were noted only in septic patients.
- Potential reasons for discrepancies in septic patients include interfering molecules or assay non-linearity.
Conclusions:
- Enzyme immunoassays are recommended for routine interleukin-6 quantification due to ease of performance.
- The 7TD1 hybridoma bioassay remains valuable when enhanced sensitivity for IL-6 detection is required.
Abstract:
As several possible prognostic and therapeutic applications of interleukin-6 are currently under trial, the available methods for its quantification in biological fluids should be evaluated. In this report, the 7TD1 hybridoma bioassay is compared to an enzyme immunoassay for the determination of interleukin-6 in serum and plasma of normal subjects and patients with cancer, sepsis, and systemic lupus erythematosus, as well as in malignant pleural effusions and culture supernatants. The results show a good correlation between the two methods in all cases. Mean values of the examined groups were statistically different between the assays only in the case of septic patients. This may be attributed either to the influence of other molecules on the assays or to the nonlinearity of the dose-response curves. Since immunoassays are easier to perform, it seems that they are more suitable for routine use, the bioassay being preferable in cases where increased sensitivity is required.
More Related Videos
11:00Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform
Published on: November 9, 2017
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
